Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Center Phase II Study of Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Patients With Extensive-Stage Small Cell Lung Cancer

Next Previous
Trial Profile

An Open-Label, Multi-Center Phase II Study of Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Patients With Extensive-Stage Small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Surufatinib (Primary) ; Durvalumab; Immune checkpoint protein inhibitors; Serplulimab; Sintilimab; Toripalimab
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Hutchison MediPharma

Most Recent Events

  • 20 Mar 2025 According to a HUTCHMED media release, results from this study will be presented at the European Lung Cancer Congress (ELCC) 2025, taking place on March 26-29, 2025 in Paris, France.
  • 04 Jun 2024 Results (As of 20 Nov, 2023, n=21) assessing safety and efficacy of surufatinib combined with PD-1/L1 inhibitors in pts with ES-SCLC as 1L maintenance therapy presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 23 May 2024 According to a HUTCHMED media release, data from this study will be presented at the upcoming American Society of Clinical Oncology Annual Meeting, taking place May 31 - June 4, 2024 in Chicago, IL and online.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top